Feb. 6, 2003 (New Orleans) — In a head-to-head study comparing intra-articular hylan GF-20 injection (Synvisc) to corticosteroid injection for knee osteoarthritis, "there was no difference in outcome ...
Genzyme Corporation today announced that the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 - 0) in favor of approval without conditions of Synvisc-One TM (hylan ...
Important Therapy Provides Six Months Pain Relief with Single Injection Genzyme Corporation (Nasdaq: GENZ) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback